Searching molecular biomarkers correlating with BSID-III at 24 months in infants with neonatal hypoxic-ischemic encephalopathy

Simple item page
dc.contributor.authorCascant-Vilaplana, Mari Merce
dc.contributor.authorPiñeiro-Ramos, Jose David
dc.contributor.authorSoláz-García, Álvaro
dc.contributor.authorLara-Cantón, Inmaculada
dc.contributor.authorIzquierdo, Isabel
dc.contributor.authorLlorens, Roberto
dc.contributor.authorMarin, Purificación
dc.contributor.authorTorres-Martínez, Ester
dc.contributor.authorMolitor, Corentin
dc.contributor.authorMohareb, Fady
dc.contributor.authorBoronat, Nuria
dc.contributor.authorQuintás, Guillermo
dc.contributor.authorKuligowski, Julia
dc.contributor.authorVento, Máximo
dc.contributor.authorHYPOTOP study group
dc.date.accessioned2024-07-24T13:29:34Z
dc.date.available2024-07-24T13:29:34Z
dc.date.freetoread2024-07-24
dc.date.issued2024-06-25
dc.description.abstractAn early prediction of outcomes of neonatal hypoxic-ischemic encephalopathy (NE) is of key importance in reducing neonatal mortality and morbidity. The objectives were (i) to analyze the characteristics of miRNA expression and metabolic patterns of neonates with NE and (ii) to assess their predictive performance for neurodevelopmental outcomes. Plasma samples from moderate/severe NE patients (N = 92) of the HYPOTOP study were collected before, during, and after therapeutic hypothermia (TH) and compared to a control group (healthy term infants). The expression of miRNAs and concentrations of metabolites (hypoxia-related and energy, steroid, and tryptophan metabolisms) were analyzed. Neurodevelopmental outcomes were evaluated at 24 months postnatal age using Bayley Scales of Infant Development, ed. III, BSID-III. Differences in miRNA and metabolic profiles were found between NE vs. control infants, abnormal (i.e., mildly and moderately abnormal and severe) vs. normal, and severe vs. non-severe (i.e., normal and mildly and moderately abnormal) BSID-III. 4-Androstene-3,17-dione, testosterone, betaine, xanthine, and lactate were suitable for BSID-III outcome prediction (receiver operating characteristic areas under the curve (AUCs) ≥ 0.6), as well as 68 miRNAs (AUCs of 0.5–0.9). Significant partial correlations of xanthine and betaine levels and the expression of several miRNAs with BSID-III sub-scales were found. Conclusion: We have identified metabolites/miRNAs that might be useful to support the prediction of middle-term neurodevelopmental outcomes of NE.
dc.description.sponsorshipThis study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “RD21/0012/0015” and co-funded by the European Union—NextGenerationEU.
dc.identifier.citationCascant-Vilaplana MM, Piñeiro-Ramos JD, Soláz-García Á, et al., (2024) Searching molecular biomarkers correlating with BSID-III at 24 months in infants with neonatal hypoxic-ischemic encephalopathy. European Journal of Pediatrics. Available online 25 June 2024
dc.identifier.eissn1432-1076
dc.identifier.urihttps://doi.org/10.1007/s00431-024-05652-x
dc.identifier.urihttps://dspace.lib.cranfield.ac.uk/handle/1826/22667
dc.language.isoen
dc.publisherSpringer
dc.publisher.urihttps://link.springer.com/article/10.1007/s00431-024-05652-x
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectmetabolomics
dc.subjectmicroRNAs
dc.subjectneurodevelopmental outcomes
dc.subjectbrain injury
dc.subjectnewborn
dc.titleSearching molecular biomarkers correlating with BSID-III at 24 months in infants with neonatal hypoxic-ischemic encephalopathy
dc.typeArticle
dcterms.dateAccepted2024-06-12

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Searching_molecular_biomarkers-2024.pdf
Size:
7.99 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
9 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Staff publications (SWEE)